Patents Examined by Dennis Heyer
  • Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications
    Patent number: 10350185
    Abstract: The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: July 16, 2019
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Sadasivan Vidyasagar, Paul Okunieff
  • Dual MAGL and FAAH inhibitors
    Patent number: 10350205
    Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: July 16, 2019
    Assignee: Abide Therapeutics, Inc.
    Inventors: Cheryl A. Grice, Justin S. Cisar, Katharine K. Duncan, Yu Feng, John J. M. Wiener, Olivia D. Weber
  • Stabilized efinaconazole compositions
    Patent number: 10342875
    Abstract: The present invention provides compositions containing efinaconazole, butylated hydroxytoluene, a salt of ethylenediaminetetraacetic acid, and optional citric acid. The compositions exhibit stable color profiles and are useful in the treatment of fungal infections.
    Type: Grant
    Filed: May 29, 2017
    Date of Patent: July 9, 2019
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Varsha Bhatt, Nayan Desai, Radhakrishnan Pillai
  • Pyrimidinones as factor XIa inhibitors
    Patent number: 10336754
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: July 2, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew K. Dilger, James R. Corte, Indawati De Lucca, Tianan Fang, Wu Yang, Yufeng Wang, Kumar Balashanmuga Pabbisetty, William R. Ewing, Yeheng Zhu, Ruth R. Wexler, Donald J. P. Pinto, Michael J. Orwat, Leon M. Smith, II
  • Composition containing non-polar compounds
    Patent number: 10335385
    Abstract: Provided are compositions and methods for producing stable foods and beverages that contain high concentrations of additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols and carotenoids; oil soluble vitamins; alpha lipoic acid; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: July 2, 2019
    Assignees: Virun, Inc., Hormel Foods Corporation
    Inventors: Philip J. Bromley, Chetan S. Rao
  • Opioid compositions resistant to overdose and abuse
    Patent number: 10335406
    Abstract: The invention provides pharmaceutical compositions comprising macromolecular gastrointestinal enzyme-labile opioid prodrugs, co-formulated with small-molecule and/or macromolecular gastrointestinal enzyme inhibitors. The macromolecular constructs are minimally absorbed from the GI tract, and can produce non-linear pharmacokinetic profiles of the delivered opioid agonist following oral ingestion. An optional macromolecular opioid antagonist may also be present in compositions of the invention to discourage tampering by potential abusers.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: July 2, 2019
    Assignee: Elysium Therapeutics, Inc.
    Inventor: Thomas E. Jenkins
  • Indole carboxamide compounds
    Patent number: 10329274
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: June 25, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qingjie Liu, Scott Hunter Watterson, John E. Macor, Khehyong Ngu, Saleem Ahmad
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10322181
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as arthritis.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: June 18, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Methods
    Patent number: 10322134
    Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 18, 2019
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Kimberly Vanover, Peng Li, Sharon Mates, Robert Davis, Lawrence P. Wennogle
  • Systems and methods for treating vitiligo
    Patent number: 10314800
    Abstract: The present invention generally relates to systems and methods for treating vitiligo. In one set of embodiments, the present invention comprises a composition comprising pyruvic acid and/or a pyruvate salt. The composition may be formulated for application to the skin of a subject, for instance, as a gel, lotion, cream, ointment, soap, or stick. In some cases, the composition may comprise a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present as a liquid crystal, and/or in liposomes, micelles, or other vesicles. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: June 11, 2019
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Methods of increasing hair growth and improving hair appearance
    Patent number: 10314775
    Abstract: In one aspect, a method of increasing hair growth includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of improving the appearance of hair includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: June 11, 2019
    Assignee: MyMD Pharmacueticals, Inc.
    Inventor: Jonnie R. Williams
  • Scalarane sesterterpenoid, pharmaceutical composition and topoisomerase II and Hsp90 inhibitor for treating cancer, and use and preparation method thereof
    Patent number: 10314847
    Abstract: The present invention discloses scalarane sesterterpenoids represented by formula (I) and meroditerpenoid represented by formula (II), which are extracted from Carteriospongia sp. sponge: where R1 is —CH3 or —C2H5. The compounds of formula (I) can be used to be an anticancer, act as an inhibitor targeting to topoisomerase II and hsp90 and a pharmaceutical composition for anticancer.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: June 11, 2019
    Assignee: National Dong Hwa University
    Inventors: Mei-Chin Lu, Ping-Jyun Sung, Jui-Hsin Su, Kuei-Hung Lai, Yi-Chang Liu, Ying-Chi Du, Yu-Ming Hsu, Ming-Kai Weng, Fu-Wen Kuo
  • Delivery of hydrophobic bioactive agents
    Patent number: 10314777
    Abstract: A composition for delivery of a hydrophobic bioactive agent is provided that provides for a partially solubilized storage solution that upon exposure to the air results in a fully solubilized bioactive agent in a molecular form for optimal delivery to the skin of a subject. The composition is used for the therapeutic treatment or diagnosis of numerous skin conditions such as inflammation, and epidermal or musculoskeletal pain.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: June 11, 2019
    Inventor: John E. Kulesza
  • Ocular formulations for drug-delivery to the posterior segment of the eye
    Patent number: 10307404
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 4, 2019
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10307484
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: June 4, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Methods and compositions for re-activating Epstein-Barr virus and screening compounds therefor
    Patent number: 10307406
    Abstract: In an effort to discover therapies for treating diseases caused by EBV, a novel screening assay for identifying compounds that reactivate EBV latent infection and a family of small molecules based on a tetrahydrocarboline backbone were discovered. Specifically, the compounds have the structure of the formula (I), wherein R1-R11 are defined herein and activate/reactivate EBV in a variety of cell types in a patient and are, therefore, useful in preventing or treating EBV-positive cancer, optionally with an anti-viral agent. In screening these compounds, novel compositions, EBV-positive cell lines, and methods are provided.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: June 4, 2019
    Assignees: The Wistar Institute of Anatomy and Biology, Drexel University
    Inventors: Paul M. Lieberman, Nadezhda Tikhmyanova-Eckert, Joseph M. Salvino
  • Method for sterilization of aqueous polysaccharide solutions and sterile aqueous polysaccharide solutions
    Patent number: 10307496
    Abstract: Sterilization method according to which an aqueous polysaccharide solution is stored in the presence of a lactone and a buffer system for a period of at least 24 hours, and a sterile polysaccharide solution produced in this way.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: June 4, 2019
    Assignee: HERAEUS MEDICAL GMBH
    Inventors: Sebastian Vogt, Thomas Kluge
  • Therapeutic combinations of sesquiterpenes and flavonoids
    Patent number: 10300040
    Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as ?-caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: May 28, 2019
    Assignee: Primus Pharmaceuticals, Inc.
    Inventor: Masayoshi Yamaguchi
  • Pharmaceutical compositions for N-propargylamine derivative
    Patent number: 10292947
    Abstract: The present application relates to a method of treating Parkinson's disease by administering a mouth-dissolving composition of N-propargylamine derivative, such as rasagiline or a pharmaceutically-acceptable salt thereof.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: May 21, 2019
    Assignee: DR. REDDY'S LABORATORIES LTD.
    Inventors: Chandrakant Bamtu Velip, Anup Avijit Choudhury, Girish Karanth, Rajeev Singh Raghuvanshi
  • Lipid-containing compositions and methods of use thereof
    Patent number: 10292958
    Abstract: Lipid compositions comprising nuts, seeds, oils, legumes, fruits, grains, and dairy useful in specified amounts as dietary supplements and diet plans designed around and including the aforementioned for the prophylaxis and treatment of numerous diseases are disclosed. The compositions include omega-6 and omega-3 fatty acids where the ratio of the omega-6 to the omega-3 fatty acids and their amounts are controlled based on one or more factors including age of the subject, sex of the subject, diet of the subject, the body weight of the subject, medical conditions of the subject, and climate of the subject's living area.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: May 21, 2019
    Assignee: ASHA NUTRITION SCIENCES, INC.
    Inventor: Urvashi Bhagat